David Roman

Q: What is David Roman's success rate?

David Roman currently has a success rate of 98.84822193488264.

Q: What is the average return of David Roman's calls?

Their stock ratings have generated an average return of 35.88283585470543.

Goldman Sachs | Healthcare

David Roman is an analyst from Goldman Sachs specializing in the Healthcare sector. Ranked #379 out of 4773 analysts, they have issued 42 stock ratings with a success rate of 98.85% and an average return of 35.88%.

David Roman has a well-established track record, with 42 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 98.85% and an average return of 35.88%, underscoring their expertise and ability to identify winning opportunities for investors.

#379

Out of 4773

Total Ratings

+98.85%

Success Rate

+35.88%

Average Return

Recent Ratings Analysis

BBNX

Buy

Jul 15, 2026

Target

$19.00

Current

$16.57

Performance

-1.72%

David Roman rated BBNX as Buy on Jul 15, 2026, setting a price target of 19. Shares have remained stable near 16.57, leaving the 19 target still in play.

BAX

Hold

Jul 15, 2026

Target

$21.00

Current

$23.80

Performance

7.45%

On Jul 15, 2026, BAX was given a Neutral rating by David Roman, with a target price of 21. The stock rallied from 23.8 to 23.8 after the Hold rating, surprising to the upside.

MDT

Hold

Jun 05, 2026

Target

$83.00

Current

$90.96

Performance

11.38%

MDT received a Neutral rating from David Roman on Jun 05, 2026, aiming for 83. Investors saw gains of 11.38% that the cautious stance didn’t fully capture.

MOBI

Buy

Jun 02, 2026

Target

$31.00

Current

$10.01

Performance

—

On Jun 02, 2026, David Roman published a Buy outlook on MOBI, with a target of 31. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 10.01.

DOCS

Hold

May 15, 2026

Target

$24.00

Current

$25.58

Performance

34.84%

David Roman on May 15, 2026 assigned DOCS a Neutral rating, with a price target of 24. Shares outperformed expectations, climbing 34.84% despite the neutral view.

GEHC

Hold

Apr 30, 2026

Target

$65.00

Current

$63.93

Performance

5.08%

On Apr 30, 2026, David Roman reaffirmed GEHC with a Neutral rating, targeting 65. Market strength beyond 63.93 went further than the conservative outlook suggested.

BSX

Buy

Apr 23, 2026

Target

$84.00

Current

$42.98

Performance

-34.57%

BSX was rated Buy by David Roman on Apr 23, 2026, with a price objective of 84. This case shows how bullish projections can fail, with the stock now below 42.98.

BDX

Hold

Apr 10, 2026

Target

$167.00

Current

$177.85

Performance

15.32%

On Apr 10, 2026, David Roman initiated coverage on BDX with a Neutral rating and target of 167. The Hold stance underestimated the stock’s strength as it gained 15.32%.

ISRG

Buy

Apr 09, 2026

Target

$609.00

Current

$369.15

Performance

-18.86%

David Roman issued a Buy recommendation for ISRG on Apr 09, 2026, price target set at 609. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

ABT

Buy

Apr 09, 2026

Target

$121.00

Current

$101.96

Performance

-0.74%

On Apr 09, 2026, ABT was evaluated by David Roman, who gave a Buy rating and target of 121. So far, the Buy call awaits clearer momentum, with shares flat at 101.96.

CARL

Buy

Apr 09, 2026

Target

$17.00

Current

$14.73

Performance

51.54%

David Roman rated CARL as Buy on Apr 09, 2026, setting a price target of 17. The call has proven timely, with shares rising 51.54% toward the price target of 17.

IRTC

Hold

Apr 09, 2026

Target

$147.00

Current

$111.43

Performance

-5.70%

On Apr 09, 2026, IRTC was given a Neutral rating by David Roman, with a target price of 147. The rating provided protection from downside risk as the stock fell to 111.43.

KMTS

Hold

Apr 09, 2026

Target

$17.00

Current

$22.85

Performance

18.70%

KMTS received a Neutral rating from David Roman on Apr 09, 2026, aiming for 17. Investors saw gains of 18.70% that the cautious stance didn’t fully capture.

OMDA

Buy

Apr 09, 2026

Target

$23.00

Current

$19.66

Performance

64.11%

On Apr 09, 2026, David Roman published a Buy outlook on OMDA, with a target of 23. Shares gained 64.11%, underscoring the accuracy of the bullish outlook toward 23.

PODD

Buy

Apr 09, 2026

Target

$277.00

Current

$131.96

Performance

-33.83%

David Roman on Apr 09, 2026 assigned PODD a Buy rating, with a price target of 277. The call has struggled to gain traction, with shares losing 33.83%.

SYK

Hold

Apr 09, 2026

Target

$357.00

Current

$275.56

Performance

-18.75%

On Apr 09, 2026, David Roman reaffirmed SYK with a Neutral rating, targeting 357. The Hold stance reflected market caution that was later justified.

TNDM

Hold

Apr 09, 2026

Target

$25.00

Current

$17.11

Performance

-13.06%

TNDM was rated Neutral by David Roman on Apr 09, 2026, with a price objective of 25. Investors who stayed cautious avoided some of the 13.06% decline.

EW

Buy

Feb 11, 2026

Target

$108.00

Current

$84.37

Performance

6.35%

On Feb 11, 2026, David Roman initiated coverage on EW with a Buy rating and target of 108. The stock’s climb of 6.35% since the call highlights the foresight in the rating.

MDLN

Buy

Jan 12, 2026

Target

$49.00

Current

$32.53

Performance

-23.85%

David Roman issued a Buy recommendation for MDLN on Jan 12, 2026, price target set at 49. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

HQY

Sell

Jan 09, 2026

Target

$89.00

Current

$96.26

Performance

2.24%

On Jan 09, 2026, HQY was evaluated by David Roman, who gave a Sell rating and target of 89. The Sell recommendation has not been clearly validated with shares unchanged at 96.26.

COO

Sell

Dec 08, 2025

Target

$71.00

Current

$53.91

Performance

-30.92%

David Roman rated COO as Sell on Dec 08, 2025, setting a price target of 71. The Sell call didn’t play out, with shares rallying -30.92% to 53.91.

BLCO

Hold

Oct 01, 2025

Target

$16.00

Current

$17.25

Performance

17.59%

On Oct 01, 2025, BLCO was given a Neutral rating by David Roman, with a target price of 16. The stock rallied from 17.25 to 17.25 after the Hold rating, surprising to the upside.

GKOS

Buy

Oct 01, 2025

Target

$103.00

Current

$167.25

Performance

101.05%

GKOS received a Buy rating from David Roman on Oct 01, 2025, aiming for 103. Momentum has favored the Buy call, with shares climbing from 167.25 to 167.25, rewarding those who trusted the recommendation.

SI

Buy

Aug 25, 2025

Target

$20.00

Current

$18.53

Performance

23.37%

On Aug 25, 2025, David Roman published a Buy outlook on SI, with a target of 20. Shares gained 23.37%, underscoring the accuracy of the bullish outlook toward 20.

ZBH

Hold

May 06, 2025

Target

$104.00

Current

$93.49

Performance

1.32%

David Roman on May 06, 2025 assigned ZBH a Neutral rating, with a price target of 104. The Hold stance reflected consolidation, as shares held near 93.49.

SOLV

Sell

Mar 03, 2025

Target

$71.00

Current

$87.45

Performance

9.09%

On Mar 03, 2025, David Roman reaffirmed SOLV with a Sell rating, targeting 71. The Sell recommendation anticipated weakness, as shares dropped 9.09%.

TDOC

Buy

Mar 03, 2025

Target

$13.00

Current

$6.16

Performance

-34.68%

TDOC was rated Buy by David Roman on Mar 03, 2025, with a price objective of 13. This case shows how bullish projections can fail, with the stock now below 6.16.

LIVN

Buy

Mar 03, 2025

Target

$55.00

Current

$78.18

Performance

87.39%

On Mar 03, 2025, David Roman initiated coverage on LIVN with a Buy rating and target of 55. The stock’s climb of 87.39% since the call highlights the foresight in the rating.

Frequency Asked Questions

Who is David Roman?

David Roman is an analyst from Goldman Sachs specializing in the Healthcare sector.

What is David Roman's success rate?

David Roman currently has a success rate of +98.85%.

How many ratings has David Roman issued?

David Roman has issued 42 stock ratings so far.

What is the average return of David Roman's calls?

Their stock ratings have generated an average return of +35.88%.

What is David Roman's ranking?

David Roman is ranked #379 out of 4773 analysts.

What types of ratings does David Roman give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow David Roman?

You can follow David Roman by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by David Roman?

Their latest rating was a Buy on BBNX issued on 2026-07-15.